When the going gets tough, grape seed extract gets going: AUniversity of Colorado Cancer Center study recently published in the journal Cancer Letters shows that the more advanced are colorectal cancer cells, the more GSE inhibits their growth and survival. On the other end of the disease spectrum, GSE leaves healthy cells alone entirely.


DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies, according to phase I clinical trial data published in Clinical Cancer Research, a journal of the American Association for Cancer Research.Daniel Vallera, PhD

“In this phase I trial, we found a safe dose of the drug that has biological activity,” said Daniel Vallera, PhD, professor of radiation oncology and director of the section on molecular cancer therapeutics at Masonic Cancer Center in the University of Minnesota in Minneapolis. “Of the 10 evaluable patients, two of them responded. We are planning a phase II trial with this drug. It will focus on giving more cycles of treatment, which we believe will dramatically enhance the response rates.”


Joanne Hilden, MD, and colleagues show that young cancer patients with fever and neutropenia have less intensive care needs and lower mortality when receiving antibiotics within an hour of arrival at the hospital.

A University of Colorado Cancer Center study published in the journal Pediatric Blood & Cancer shows that pediatric cancer patients who receive antibiotics within 60 minutes of reporting fever and showing neutropenia (low neutrophil count), go on to have decreased intensive care needs and lower mortality compared with patients who receive antibiotics outside the 60-minute window.

“We’re talking about kids who have gone home after chemotherapy and then a parent calls the hospital reporting a fever. The question is can we get the patient back to the hospital, then get a white cell count, and get antibiotics on board when needed all within an hour of their arrival? It’s a huge challenge. This study shows that it’s important we make it happen: there’s less intensive care and fewer fatalities for kids who get antibiotics sooner,” says Joanne Hilden, MD, investigator at the CU Cancer Center, director of clinical services for pediatric oncology at Children’s Hospital Colorado, and the paper’s senior author.

Specifically, the paper shows in a sample of 220 children that mortality was 3.9 percent for patients who received antibiotics outside 60 minutes and only 0.7 percent for those who received antibiotics within the hour.

Go to top
JSN Boot template designed by